Omega Diagnostics Share Discussion Threads

[longshanks] 13/5/2015 10:21

Bought a few more.

[longshanks] 12/5/2015 19:21

Chart starting to look very nice. 200d m.a. now showing with an upward trajectory and a clear golden cross of 30d over the 50d moving average.


free stock charts from uk.advfn.com


Might see a little more downward pressure but, for me, this is now a very strong recovery play. The fundamentals back this up of course with impending news later this month.

[barrywhit] 06/5/2015 11:01

Thanks for that Rivaldo.

That's 3 recommendations/write ups since the trading update...very positive...imo

[rivaldo] 06/5/2015 09:14

Farmsted, yes. But hopefully starting very soon after the May CD4 update....

ODX are tipped/covered in the new May issue of Master Investor magazine here on page 46....



Got no idea how to copy or paste from it, but it's a decent intro to CD4 and its potential.

[farmsted] 05/5/2015 08:56

When do hope for this to happen, 2016 ?

[leedslad001] 29/4/2015 17:22

Agree onwards and upwards

[longshanks] 29/4/2015 13:50

They are so right....

[rivaldo] 29/4/2015 13:49

The Faraday tip has been partly posted elsewhere as follows - and it doesn't even mention the potential of the allergy development programme....

"What’s really got our attention is the huge potential of VISITECT and the fact this doesn’t seem to be fully priced in by the market. There are no guarantees as to exactly when it will be launched and we may need to be patient.

But when it does finally happen the shares should rise significantly, with a re-rating looking quite likely."

"Even with just a return to last year’s high of 31.6p (before the VISITECT trial issues) Omega shares would still offer investors 75% of upside.

VISITECT could be a game changer
• Commercial launch in sight
• More exciting products in the pipeline
• Profit ahead of expectations
• Newsflow could trigger a re-rating

After trials of its revolutionary new HIV testing device were held up last year, shares in Omega Diagnostics pulled backed. The issues causing these problems have been corrected and the device is now on course for commercialisation. We feel this isn’t full priced in and the shares are significantly undervalued."

[longshanks] 29/4/2015 09:56

This chart is looking pretty - very pretty. :)

[longshanks] 29/4/2015 09:49

Couldn't resist - another 37.5k for the bottom drawer....

[rivaldo] 29/4/2015 08:30

Thx tony773 - got a link at all?

[barrywhit] 29/4/2015 08:23

cheers tony773....

[tony773] 29/4/2015 07:35

just been recommended by Faraday research

[longshanks] 28/4/2015 13:55

People buy; people sell its what the market is there for.Liquidity is shocking in these small caps and that can cause the price to swing quite dramatically. The price here is underpinned by fairly strong fundamentals and some mouthwatering potential and that is what I am here for. One could try trading the volatility (and I am sure some are) but I am happy to lock mine down for the next 18 months minimum.

[barrywhit] 28/4/2015 11:11

Large delayed sell this morning 176k...strange time to sell with the update next month..

[longshanks] 27/4/2015 21:08

For those that follow such things, the 30d moving average has now converged on and ready to cross the 50d. Both are on an upward trajectory and for me this is a really bullish signal.Broker estimates are sensibly conservative and that is fine and of course provides plenty of scope for the company to post news in time that they are trading ahead of expectations.

[barrywhit] 27/4/2015 20:45

Valuation: Visitect launch timing key to adding value
The ratio of the market cap to historic FY15 sales is 1.5x with a prospective FY16 P/E of about 11.8x; both indicate medium-term growth expectations. No FY16 Visitect or allergy iSYS sales are forecast so the FY16 sales estimates have been lowered; cash use is slightly higher as R&D is taking longer. Reported profit is affected by the non-cash charges (about £0.6m) and R&D capitalisation, assumed to be £1.6m in FY15. If Visitect and allergy iSYS are ready for sale in FY17, Omega should enter a sustained growth phase; Visitect uptake could then be very rapid.

[hyperboreus] 27/4/2015 16:03

It will be interesting to see exactly what the salary and benefits package will be for Colin King as the latest figures I can unearth for him at Axis-Shield are:

'The highest-paid director Colin King received a total package of £197,388 for the year to 31 December 2013, up from £183,791 in 2012.'



By comparison Omega Executive Director's respective salaries for both 2013 & 2014 was as follows:

Andrew Shepherd £145,000
Kieron Harbinson £115,000
Jag Grewal £110,000

[barrywhit] 27/4/2015 15:17

All looking very promising...

[rivaldo] 27/4/2015 11:09

Worth noting the forecasts of 1.3p historic EPS and 1.4p EPS this year, with hopefully Visitect and allergy iSYS sales coming through the year to March'17 (and perhaps even sooner if all goes well).

[andrbea] 27/4/2015 10:40

Edison report on odx

Omega’s FY15 trading update reported that the Visitect CD4 test for HIV
monitoring is making “good” progress with management “very confident”
that the test variability causes can be resolved. Customer site evaluations
on allergy iSYS (using 27 optimised allergens) are being planned to lead
towards product launch. For FY15, management guides about 27% growth
in adjusted PBT to about £1.4m on overall test sales of £12.1m, up 4%.
Food intolerance performed well with 15% growth; manual allergy sales
were down 9%, but there was some growth in infectious disease, up 4%
after a long period of decline. Mr Colin King is joining as COO on 3 August.

[longshanks] 27/4/2015 09:36

Not sure about that bw. The closed period has ended and the BoD have given full disclosure on progress to date. It is only if there are market sensitive insider details outstanding that Directors would be prohibited.Not really a big deal - the news by end of May is the big ticket item; it just adds to the story...

[rivaldo] 27/4/2015 08:41

Excellent appointment today - Colin King and Evans obviously have a very strong relationship, and King would not have joined form ASD, which is still thriving in its own right under Alere given the success of Afinion, unless there are serious and encouraging prospects here.

The update next month will be worth watching out for methinks.

[barrywhit] 27/4/2015 08:16

With the update in approx. 4 weeks for the 2 company changing products, it is a very exciting time to be invested in this company....

longshanks, i'm not sure if the directors can purchase shares knowing there is the update at the end of May.....

[barrywhit] 27/4/2015 07:54

Dibs, his company were acquired by Alere.. Alere have their own CD4 test so his appointment is very interesting.......imho